Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPI-613 with Induction/Consolidation in Older AML
NCT02472626Phase 2Withdrawn
- Sponsor
- Wake Forest University Health Sciences
- Start
- Dec 2015
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of devimistat in acute myeloid leukemia (AML), sponsored by Wake Forest University Health Sciences. Primary endpoints: Maximum Tolerated Dose at 14 days and Rate of Complete Remission at 2 years. Planned start Dec 2015; status: withdrawn.
02
Drugs
devimistat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02472626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02472626.